A Multicenter Open-Label Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT #
NCT05379985
Condition(s)
Colorectal Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Solid Tumor
Molecular Target(s)
KRAS G12, KRAS G12C, KRAS G12D, KRAS MUTATION
Drug Classification(s)
Small Molecule
Agents(s)
RMC-6236
Phase(s)
I
Mechanism of Action
RMC-6236 inhibits the RAS(ON) state of multiple RAS variants both mutant and wild-type proteins.
Purpose
- How much of the study drug can be given with an acceptable level of side effects
- The effects of the study drug (good and bad)
- How much of the study drug is absorbed into the blood and how fast it is removed
- If research tests can be used in the future to predict who will benefit from the study drug
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.